Clinical Trials Logo

Advanced Colorectal Cancer clinical trials

View clinical trials related to Advanced Colorectal Cancer.

Filter by:

NCT ID: NCT04337879 Recruiting - Clinical trials for Advanced Colorectal Cancer

A Study of AL2846 Capsule Combined With Standard Chemotherapy Regimen in Subjects With Advanced Colorectal Cancer

Start date: July 20, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a study to explore the safety, tolerance and efficacy of AL2846 capsules combined with mFOLFOLX6 or FOLFIRI standard chemotherapy regimen in subjects with advanced metastatic colorectal cancer.

NCT ID: NCT04324476 Recruiting - Clinical trials for Advanced Colorectal Cancer

A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer

Start date: September 1, 2019
Phase: Phase 2
Study type: Interventional

The objective is to investigate the efficacy and safety of two-weekly alternative regimen of Bevacizumab plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer.

NCT ID: NCT04252456 Recruiting - Clinical trials for Advanced Colorectal Cancer

Folfiri/aflIbercept in Metastatic coloreCTal Cancer patIents With RAS Validated Wild typE Status

DISTINCTIVE
Start date: April 23, 2018
Phase: N/A
Study type: Interventional

The study will a be a biologically enriched, prospectively stratified phase II trial in RAS wild type metastatic colorectal cancer patients progressing after first-line treatment with oxaliplatin, fluoropyrimidines and an anti-EGFR monoclonal antibody. All patients will receive aflibercept in combination with FOLFIRI according to the Italian label.

NCT ID: NCT03699111 Completed - Clinical trials for Advanced Colorectal Cancer

Identification of New Patient Stratification Tools in MSS RAS mt mCRC

COLOSSUS
Start date: September 19, 2018
Phase:
Study type: Observational

This is a translational, multicentre and multinational study. The aim of this study is to identify new patient stratification tools in microsatellite stable RAS mutant metastatic Colorectal Cancer

NCT ID: NCT03524274 Withdrawn - Clinical trials for Advanced Colorectal Cancer

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Colorectal Cancer

Start date: April 5, 2018
Phase: Phase 2
Study type: Interventional

This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1 bispecific antibody for advanced colorectal cancer. And the aim of this research is to study the clinical efficacy and safety of activated CIK armed with anti-CD3-MUC1 bispecific antibody for colorectal cancer.

NCT ID: NCT03427268 Completed - Clinical trials for Advanced Colorectal Cancer

Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment

Start date: January 16, 2018
Phase: Phase 2
Study type: Interventional

This trial will evaluate the efficacy of PM060184 in terms of progression-free survival at 12 weeks (PFS3) in advanced or metastatic Colorectal Cancer (CRC) patients with any KRAS mutation status (wild- type; mutated; or unknown status) progressing after standard treatments (fluoropyrimidine, irinotecan, and oxaliplatin). Patients in this trial will receive PM060184 at a dose of 9.3 mg/m2 as a 30-minute intravenous (i.v.) infusion on Days 1 and 8 q3wk.

NCT ID: NCT03311750 Terminated - Clinical trials for Advanced Colorectal Cancer

Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer

A-REPEAT
Start date: March 26, 2018
Phase: Phase 2
Study type: Interventional

A-REPEAT (Anti-Epidermal Growth Factor Receptor -EGFR- rechallenge and plasma genotyping of patients with advanced colorectal tumors) is a Greek, investigator-initiated, single arm open-label phase II study of anti-EGFR therapy rechallenge in combination with chemotherapy in patients with advanced colorectal cancer. Patients with a metastatic, histologically proven colorectal carcinoma RAS wild type will be treated with a combination of panitumumab and third-line irinotecan-based or oxaliplatin-based chemotherapy (FOLFOX,FOLFIRI or irinotecan monotherapy).

NCT ID: NCT03126071 Recruiting - Clinical trials for Advanced Colorectal Cancer

Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer

Start date: February 15, 2017
Phase: Phase 2
Study type: Interventional

The objective is to investigate the efficacy and safety of raltitrexed-based chemotherapy plus bevacizumab in the treatment of advanced colorectal cancer

NCT ID: NCT02923622 Not yet recruiting - Clinical trials for Advanced Colorectal Cancer

Efficacy and Safety Evaluation of Traditional Chinese Medicine in the Treatment of Advanced Colorectal Cancer

Start date: September 2016
Phase: N/A
Study type: Observational

Although patients of colorectal cancer use Traditional Chinese Medicine (TCM) herbal therapy extensively in China, no strong evidence exists to demonstrate the safety and survival outcomes of TCM herbal therapy combined with conventional western medicine for treatment of this disease. The purpose of this multi-center perspective cohort study is to evaluate the relationship between TCM herbal therapy and survival outcomes in patients with advanced colorectal cancer.

NCT ID: NCT02826837 Not yet recruiting - Clinical trials for Advanced Colorectal Cancer

LEAC-102 for Advanced Colorectal Cancer

Start date: September 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of LEAC-102 in Combination with FOLFOX + Bevacizumab/Cetuximab in Subjects with Advanced Colorectal Cancer